GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Zhejiang Huahai Pharmaceutical Co Ltd (SHSE:600521) » Definitions » Research & Development

Zhejiang Huahai Pharmaceutical Co (SHSE:600521) Research & Development : ¥1,012 Mil (TTM As of Mar. 2025)


View and export this data going back to 2003. Start your Free Trial

What is Zhejiang Huahai Pharmaceutical Co Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Zhejiang Huahai Pharmaceutical Co's Research & Development for the three months ended in Mar. 2025 was ¥239 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2025 was ¥1,012 Mil.


Zhejiang Huahai Pharmaceutical Co Research & Development Historical Data

The historical data trend for Zhejiang Huahai Pharmaceutical Co's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zhejiang Huahai Pharmaceutical Co Research & Development Chart

Zhejiang Huahai Pharmaceutical Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 565.70 942.26 925.53 982.99 986.69

Zhejiang Huahai Pharmaceutical Co Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 213.86 226.10 247.50 299.23 238.91

Zhejiang Huahai Pharmaceutical Co Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥1,012 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Zhejiang Huahai Pharmaceutical Co  (SHSE:600521) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.


Zhejiang Huahai Pharmaceutical Co Research & Development Related Terms

Thank you for viewing the detailed overview of Zhejiang Huahai Pharmaceutical Co's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.


Zhejiang Huahai Pharmaceutical Co Business Description

Traded in Other Exchanges
N/A
Address
Xunqiao, Zhejiang Province, Linhai, Linhai, CHN, 317024
Zhejiang Huahai Pharmaceutical Co Ltd is engaged in Research & Development, production and sales of multi-dosage preparations, biological drugs, innovative drugs and specialty APIs.
Executives
Lin Li Hong senior management
Xu Mi senior management
Gang Hui senior management
He Bin senior management
Kong Xiao Fang senior management
Chen Bao Hua Director
Shang Fei senior management
Du Jun Director
Su Yan Director
Chen Dun Yuan senior management
Li Hong Director
Guo Si Jia senior management
Li Min senior management
Xu Bo senior management
Chen Qi Mao senior management

Zhejiang Huahai Pharmaceutical Co Headlines

No Headlines